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1. Introduction
   
   For the past few years, combination of neural stem cells 
(NSCs) transplant and gene therapy has been one of the 
hotspots in the study of spinal cord injury treatment. After 
the injury of spinal cord, massive nervous structures will 
be destroyed because of primary injury and secondary 
inflammatory changes. And formation of glial scar 
contributes further to the damage of stem cell niche for 
nerve regeneration, leading to the regenerative difficulty of 
nerves. Hence, ideal clinical therapy for spinal cord injury 
is yet to be developed at present. It has been found that 
after the transplant few neural stem cells will differentiate 
into neuronic and most of the cells will differentiate into 
neurogliocyte, which contribute nearly no repairing effect 
to spinal cord injury[1]. While, if gene therapy is employed 
in addition to neural stem cell transplant to modify the 
transplanted cells and decrease the formation of glial 
scar, inducing its differentiation toward neurogliocyte and 
optimizing the regeneration conditions, it is hopeful to 
achieve better effect in the treatment of spinal cord injury.  
   Therefore, the present study is aimed to modify the 
genes related to the above mentioned two aspects. It has 
been shown in past studies that inflammation reaction 
and formation of glial scar can be effectively inhibited 
by blocking the action of TNF毩 using soluble TNF alpha 
(sTNFR栺) receptor receptor[2,3], and neurotrophic factor 
human glial cell line-derived neurotrophic factor (hGDNF) 
can induce the differentiation of neural stem cells towards 
neurons, overcoming the draw backs of differentiation 
towards multidirectional astroglia by neural stem cells 
transplant treatment alone[4-6]. Hence, the present study 
is aimed at construct adenovirus vectors that could be 
used in the expression of TNF毩栺receptors and GDNF and 
transfect neural stem cells, facilitating further study in the 
treatment of spinal cord injury with combination of stem 
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cell transplant and gene therapy.
2. Materials and methods
2.1. Separation and cultivation of neural stem cells
   The aborted twelve-week human embryo was employed 
in the study (Informed consent was obtained from Ethical 
Committee of Shenzen Guanlan People’s Hospital and 
the pregnant woman). After being soaked in 75% ethyl 
alcohol, the pallium tissue of the embryo was separated 
immediately under aseptic condition and washed in 4 曟 
D-Hank’s solution for three times. The tissue was cut up, 
added into DMEM/F12, blown and hit gentlely, and then 
screened by 200-毺m cell strainer. The screened tissue was 
then inoculated into culture flakes at 5暳10
5 per flake and 
incubated in 5% CO2, at 37 曟. The constituents of culture 
medium are DMEM/F12 (1∶1), supplementary culture 
medium B27 (all purchased form Gibco Company), 20 ng/
mL epidermal growth factor (EGF) and 20 ng/mL bFGF (all 
purchased from Pepro Tech Company). The culture solution 
was replaced every three days, and passage of the cells 
was performed every 7-10 days. The method utilized for 
cell passage was mechanical isolation. The neurospheres 
were cut into pieces using dedicated cutting equipment, 
blown and hit to make a single-cell suspension and then 
inoculated into new culture flakes after counting.
2.2. Construction and identification of the recombinant 
adenovirus vector
2.2.1. Construction and identification of human GDNF 
recombinant adenovirus vector
   The methods for the construction and identification 
of human GDNF recombinant adenovirus vector were 
present in the previous published paper of our research 
group. The pLNCX2/GDNF plasmid (provided by Institute 
for Neuroscience Research, Capital Medical University) 
was double digested by Bgl栻 and Hind栿 enzymes. After 
identified by agarose electrophoresis, the sequence was 
detected (Beijin AuGCT Biology Co., Ltd.), and compared 
with human GDNF (hGDNF) sequence in Genebank. And Bgl
栻 and Hind栿 enzymes were used to digest pLNCX2/GDNF 
plasmid and pAdtrack-CMV plasmid respectively after 
the identification. The needed fragments were screened by 
determining the molecular weight in agarose electrophoresis 
and then recombined with T4 ligase. The ligased products 
were used for the transformation of DH5毩competent cells. 
And then the needed cells were cloned and double digested 
by Bgl栻 and Hind栿 enzymes to determine the positive 
clone.
   pAdtrack-CMV plasmid (named asp Adtrack-CMV- 
hGDNF plasmid) containing hGDNF were screened. 2 毺L 
Adeasy-1 plasmid and 5 毺L (200 ng) Adtrack-CMV- hGDNF 
plasmid were transformed into BJ5183 competent cells at 
the same time to obtain recombinant (named as pAdeasy- 
hGDNF plasmid). The transformation condition, methods and 
identification could be referred to published paper[7].
2.2.2. Construction and identification of soluble human TNF
毩 receptor recombinant adenovirus vector 
   RT-PCR method was used in the extraction of total 
RNA from U937 cells, and extracellular fragments (275-
772 bp) TNFR type栺were amplified using the RNA as 
template. The primers for amplification are: P1 (5’-
CAGGATCCGATAGTGTGT2GTCCCCAAG-3 ’ )  and  P2 
(5’-CCCAAGCTTCTCAGTGCC2CTTAACATTC-3’ ) .  The 
amplification was conducted in a reaction system of 50 毺L 
volume: reverse transcription were performed at 48 曟 for 45 
min, then the obtained products were denatured for 2 min at 
90 曟. Thirty PCR recycles were then performed (denatured 
for 30 s at 94 曟, cooled for 1 min at 60 曟, extended for 1 
min at 68 曟), and the fragment were extended for 7 min at 
68 曟. The obtained PCR amplified fragments were identified 
by 2% agarose gel electrophoresis containing EB.
   The cDNA of targeted fragment and pET28a vector were 
double digested by Bgl栻 and Hind栿 enzymes, respectively, 
recombined. The recombinant products were used for the 
transformation of DH5毩 competent cells. 
2.3. Packaging of the corresponding adenovirus vector
2.3.1. Packaging of the adenovirus vector
   The above mentioned two kinds of adenovirus were 
packed using similar methods. The kidney cells of human 
embryo HEK293A were inoculated in 25 mL cultural flakes at 
1暳10
5 per flake. When the density of cells reached to 50%-
70%, the linearized pAdeasy-hGDNF plasmid and pAdeasy- 
sTNFR栺plasmid by Pac栺enzyme were transfected into 
the kidney cells of human embryo cells. Six hours later 
the culture were transferred into completed DMEM culture 
medium containing 10% bovine serum and incubated for 
7-10 days. The culture solution was refreshed every 3 days, 
and the expression of the targeted genes was observed 
regularly.
2.3.2. Identification of adenovirus vector
   On the seventh day after the transfection, the HEK293A 
cells were collected using conventional method under aseptic 
condition. after being resuspended by PBS, the cells were 
repeatedly freezed and freeze-thawed for 4 times at -20 曟 
and 37 曟, and then centrifuged (1 2000 r/min) for 10 min at 
4 曟 to obtain the suspension. Five micro liters of suspension 
was digested by K Protease at 55 曟 for an hour, and boiled 
for 5 min, and the identification was performed by PCR. 
Two primers were used in the identification of hGDNF gene, 
thus, upstream: 5’-CCACCATGAAGTTATGGGATGTCGT-3’ 
and downstream: 5’-TCAGATACATCCACACCTT-3’. The 
hGDNF gene was pre-denatured for 3 min at 94 曟 and then 
45 seconds at 94 曟, 1 min at 60 曟, 1 min at 72 曟, the total 
cycles were 30, and finally extended at 72 曟 for 10 min. 
For the identification of sTNFR栺gene, the primers are 
upstream 5’-CAGGATCCGATAGTGTGT2GTCCCCAAG-3’, 
and downstream 5’-CCCAAGCTTCTCAGTGCC2CTTAACATTC-3’.
The reactions were carried out as follows: 3 min initial 
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denaturation of sTNFR栺gene at 94 曟, followed by 30 cycle 
of 30 second denaturation at 94 曟, 1 min annealing at 60 曟 
for 1 min, and 1 min extension at 68 曟. Finally extended at 
68 曟 for 7 min.
2.4. Transfect ion of adenovirus into neural stem cells and the 
identification of the expressed product of the targeted gene
   After neural stem cell propagation for 48 h, 1暳10
8 PFU 
(colony forming unit) titers of the virus supernatant were 
added into two bottles of the cell culture, of which one was 
added transfected virus with targeted gene hGDNF and 
sTNFR栺to serve as experimental group and the other was 
added empty vector virus supernatant as control. After two 
days of transfection. The supernatant of the cell culture in 
both experimental group and control group were collected 
to detect the expression of gGDNF and sTNFR栺gene (ELISA 
kit purchased from R&D Company). And the culture 
temperature were altered from 37 曟 to 30 曟 to decreased 
the output of the targeted gene. The total cell proteins were 
collected two days later to detect the expression status of 
the targeted gene using WB methods (antibodies purchased 
from Santa Cruz Company). Fluorescence microscope was 
employed to observe the expression status of the targeted 
gene in the transfected neural stem cells before protein 
collection.
2.5. Identification of the neural stem cells and its 
differentiation
   Immunofluorescence staining was performed to identify 
neural stem cells and its differentiation. Neurospheres 
were stained by Nestin antibody and immunofluorescence 
positive staining shows the presence of neural stem cells. 
Glial fibrillary acidic protein (GFAP) antibody and Tubulin 
antibody were used to stain four-week trangenic cells. 
Positive staining of both the proteins showed the presence 
of neuron and axons. The staining methods were followed as 
the corresponding antibody instruction.
3. Results
3.1. Construction and identification of hGDNF and sTNFR I 
gene recombinant adenovirus vector
   By digesting pLNCX2/GDNF plasmid using Bgl栻 and Hind
栿enzymes, hGDNF gene of 558 bp was obtained (Figure 
1). The length of the amplified sTNFR栺cDNA was around 
504 bp (Figure 1B). As shown in figure 1C, after digested 
by BamH栺and Hind栿 enzymes the vector fragment 
and targeted gene which were consistent with theoretical 
value were obtained from recombinant pET-28a/sTNFR栺
plasmid (Lane 3 and 2 are targeted gene fragment). After 
recombinating with adenovirus and being digested by Pac
栺enzyme, two fragments of 3.0 kb and 2.9 kb were obtained 
from pAdeasy-hGDNF plasmid and pAdeasy-sTNFR栺
plasmid, respectively (Figure 1D lane 3 and lane 2).
4 000 bp
1 000 bp
500 bp
A                                                            B
1 543 bp
994 bp
647 bp
515 bp
C                                                            D
5 148 bp
564 bp
5 kb
3 kb
Figure 1. Construction and identification results of hGDNF and 
sTNFR栺gene recombinant adenovirus vector. 
A: pLNCX2/GDNF plasmid was digested by Bg1栻 and Hind栿 
enzymes to obtain gene vector and 558 bp hGDNF gene fragment (Lane 
2), lane 3 represent the undigested vector. B: 504 bp sTNFR栺cDNA 
obtained using RT-PCR amplification. C: Identification result of pET-
28a/sTNFR栺enzyme digestion. Lane 2: 504 bp targeted gene, lane 3: 
Targeted gene after enzyme digestion and vector fragment. D: The 
obtained fragment after the digestion by Pac栺enzyme in pAdeasy- 
hGDNF (Lane 3) and pAdeasy- sTNFR栺(Lane 2).
3.2. Packaging and identification of adenovirus containing 
targeted gene
2 000 bp
500 bp
100 bp
Figure 2. Identification of hGDNF and sTNFR栺genes in 
supernatant of virus using PCR. Lane 2: 558 bp hGDNF gene, lane 
3: 504 bp sTNFR栺gene.
   Five days after the transfection into 293A cells, obvious 
hGDNF gene infected cells were observed with presence of 
green fluorescence protein using fluorescence microscope. 
And sTNFR栺gene infected cells were observed with 
presence of red fluorescence protein. A great quantity 
of EGFP and RFP were observed in some neural stem 
cells, which indicated the expression of both GDNF and 
sTNFR栺. The supernatant of the virus were collected on 
the eighth day and detected by PCR. The obtained specific 
558 bp targeted band was hGDNF gene (Figure 2, lane 2), and 
the 504 bp band was sTNFR栺gene (Figure 2, lane 3).
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3.3. Expression status of the targeted gene in adenovirus 
infected neural stem cells 
   After the infection of adenovirus, the expression of GDNF 
and sTNFR栺gene was observed to be increased obviously in 
the supernatant of the culture by ELISA detection (Figure 3A 
and B). Increased expression could be detected by Western 
blot methods in cells cultured under low temperature to 
decrease the output of targeted protein (Figure 3C and D), 
which validated the effectiveness of this method.
 
3.4. Detection of the neural stem cells and its differentiation
   A large quantity of cells showed Nestin positive staining 
after the immunofluorescence staining in neurosphere 
(Figure 4A), which showed that the neurosphere retained 
the characteristics of neural stem cell in vitro.Four weeks 
after the infection of adenovirus, the cells were stained with 
immunofluorescence. The GFAP positive cells (green) also 
showed Tubulin positive areas (red), which meant that most 
neural stem cells differentiated into neuron at that condition 
(Figure 4B).
4. Discussion
   The studies of NSC are mainly focused on NSC transplant to 
treat brain lesion and spinal cord injury, which is considered 
to be a promising therapy[8-10]. However, to achieve an ideal 
effect, the problems of long term survival and directional 
differentiation of the NSCs must be solved. While, to induce 
the committed differentiation of NSCs into neurons and to 
optimize the niche for the regeneration of the nerves will 
greatly enhance the effect of stem cell transplant. 
   A relatively high concentration of neurotrophic factor 
around the transplanted cells is important for the survival 
and committed differentiation of the cells[11].It has 
been shown that many neurotrophic factors including 
nerve growth factor, eurotrophy (NT-3), brain-derived 
neurotrophic factor, etc[12] can facilitate the differentiation 
of the NSCs into neurons. As a peptides growth factor in 
TGF-毩family, GDNF is a kind of secretory protein which 
can promote the growth of neuron, increase the nerve fiber 
and enhance the secretion level of dopamine[4,5]. It can also 
protect dopamine neurons and motor neurons from injury 
and improve the function of central nervous system [13]. In 
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Figure 3. Expression status of hGDNF and sTNFR栺gene in culture supernatant and adenovirus infected NSCs.
Figure 4. Immunofluorescence staining of NSCs and its differentiation.
A: Nestin antibody staining in neurosphere, B: Four weeks after the infection of adenovirus, GFAP (green) and Tubulin antibody staining.
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our earlier studies, GDNF gene recombinant adenoviruses 
were successfully imported into NSCs and expressed, 
increasing the neurotrophy concentration around the NSCs 
and inducing the differentiation of NSCs towards neurons.
   However, except the obvious influence of the local 
neurotrophy factor on the committed differentiation of 
NSCs, the negative effect of the inflammatory mediators in 
the growth niche should also be eliminated [14,15]. After the 
spinal cord injury, the massive release of inflammatory 
mediators will lead to the destroy of nervous structure and 
the formation of glial scar, worsening the niche for nervous 
regenaration.It has been proven that TGF-毩is the main 
medium in the inflammatory reaction.After the injury of 
the surrounding nerves, the TGF-毩in the vervous system 
is mainly synthesized and released by macrophage and 
schwann cell or by astroglia and microglia in central nervous 
system, which plays an important role in the pathological 
physiology process in the injury of central nervous system.
TGF-毩realizes its biological function by combining with 
the TGF-毩receptors on the cell membrane and activating 
signaling pathway in the cells. Soluble TNFR can combine 
with TGF-毩specifically and decrease the biological activity 
of TGF-毩, which make it a therapy for the treatment of 
TGF-毩mediated diseases[2,3,16]. Hence, in the present 
study, except for providing high concentration of growth 
factor for NSCs through transinfecting GDNF gene, soluble 
TGF-毩receptor was also transplanted to block the injury 
of excessive TGF-毩on NSCs, optimizing the growth and 
differentiation niche in two aspects.
   The study of optimizing NSCs regeneration niche includes 
direct injection of growth factor in pivot, transplant of brain 
tissue processed by growth factors in embryo, local injection 
of transplant and virus mediated growth factor gene therapy, 
etc[17]. And gene therapy receives widely emphasis because 
of it obvious application prospects[18]. In gene therapy, 
recombinant adenovirus with cloning defects has been 
used widely in clinical treatment as effective gene vector 
because of its high transfer efficiency and non chromosomal 
integration incidence. Although the most widely used vector 
in GDNF mediated gene therapy is retrovirus vector because 
its exogenous gene could be integrated into cell genomes 
to realize its expression, retrovirus only infect cells in split 
period and has very low infection rate in NSCs[19]. While 
recombinant adenovirus has a relatively high infection 
rate in NSCs and cells in quiescent and split period. In 
addition, brain and spinal cord are partial immune privilege 
organ, adenovirus can express for several weeks without 
eliciting inflammatory reactions[20]. Hence, the present study 
employed adenovirus to transfect GDNF gene and obtained 
expected effect. And good effect were also achieved in the 
transplant of sTNFR栺using adenovirus. The differentiation 
of NSCs into neurons and formation of axons proves that the 
present gene therapy could achieve a well effect in vitro, 
which facilitates the further in vivo study.
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